Safe and effective booster immunization using DTaP in teenagers

Okada, Kenji; Komiya, Takako; Yamamoto, Akihiko; Takahashi, Motohide; Kamachi, Kazunari; Nakano, Takashi; Nagai, Takao; Okabe, Nobuhiko; Kamiya, Hitoshi; Nakayama, Tetsuo

doi:10.1016/j.vaccine.2010.09.050

Cited by 22 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 0.5 ml of DTaP vaccine (Kaketsuken) contains the same dose of PT and higher doses of FHA, D, and T than the Boostrix Tdap (13) and higher doses of PT, FHA, D, and T than the Adacel Tdap (12), which is used abroad (14) ( Table 6). However, immunogenicities against PT in this study were sufficient despite 0.2 ml of DTaP, results which are very similar to those of previous reports (12)(13)(14)21). The most common local reactions reported in our study were erythema, swelling, and pain.…”

Section: Discussionsupporting

confidence: 92%

“…With regard to the prevaccination antibody level, we observed antibody levels against PT and FHA that were lower than those in previous studies (14,21). Thus, immunogenicities in our subjects may have been lower than those of the previous studies if the components of the vaccine were the same.…”

Section: Discussioncontrasting

confidence: 79%

“…In our study, the prevaccination antibody seropositivity rates against pertussis were around 40% for PT and 70 to 80% for FHA, which are lower than those reported in Japanese adolescents (14) and Finnish young adults (21). In the former study, seropositivity rates against pertussis were 52 to 59% for PT and 79 to 86% for FHA among the adolescents, who were immunized for pertussis about 10 years prior (14). In the latter study, seropositivity rates at 10 years after the fifth dose of Tdap were 61.3% for PT and 100% for FHA (21).…”

Section: Discussioncontrasting

confidence: 79%

“…Limits of quantification for each antibody against PT, FHA, D, and T were 1.0 EU/ml, 1.0 EU/ml, 0.005 IU/ml, and 0.005 IU/ml, respectively. Seropositive levels were defined as Ն10 EU/ml for antibodies against PT and FHA, Ն0.1 IU/ml for diphtheria antitoxin, and Ն0.01 IU/ml for tetanus antitoxin (14). A booster response for PT and FHA was defined as a postvaccination antibody concentration of Ն20 EU/ml with a prevaccination antibody concentration of Ͻ5.0 EU/ml, a postvaccination rise of at least 4 times the prevaccination antibody concentration in subjects with a prevaccination antibody concentration of 5.0 to 20 EU/ml, or at least twice the prevaccination antibody concentration in subjects with a prevaccination antibody concentration of Ն20 EU/ml.…”

Section: Methodsmentioning

confidence: 99%

“…Since Tdap has not yet been licensed in Japan, DTaP may be available for booster immunization in the interim. Safe and effective booster immunization using DTaP in adolescents has been confirmed (14); however, little is known about the immunogenicity and safety of the DTaP vaccine in young adults. In this study, we examined the immunogenicity and safety of 0.2 and 0.5 ml of DTaP in young adults in Japan.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Immunogenicity and Safety after Booster Vaccination of Diphtheria, Tetanus, and Acellular Pertussis in Young Adults: an Open Randomized Controlled Trial in Japan

Hara

Okada

Yamaguchi

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

The recent increase of pertussis in young adults in Japan is hypothesized to be due in part to waning protection from the acellular pertussis vaccine. While a booster immunization may prevent an epidemic of pertussis among these young adults, little is known about the safety and immunogenicity of such a booster with the diphtheria, tetanus, and acellular pertussis vaccine (DTaP), which is currently available in Japan. One hundred and eleven medical students with a mean age of 19.4 years were randomly divided into 2 groups of 55 and 56 subjects and received, respectively, 0.2 or 0.5 ml of DTaP. Immunogenicity was assessed by performing the immunoassay using serum, and the geometric mean concentration (GMC), GMC ratio (GMCR), seropositive rate, and booster response rate were calculated. Adverse reactions and adverse events were monitored for 7 days after vaccination. After booster vaccination in the two groups, significant increases were found in the antibodies against pertussis toxin, filamentous hemagglutinin, diphtheria toxoid, and tetanus toxoid, and the booster response rates for all subjects reached 100%. The GMCs and GMCRs against all antigens were significantly higher in the 0.5-ml group than in the 0.2-ml group. No serious adverse events were observed. Frequencies of local reactions were similar in the 2 groups, although the frequency of severe local swelling was significantly higher in the 0.5-ml group. These data support the acceptability of booster immunization using both 0.2 and 0.5 ml of DTaP for young adults for controlling pertussis. (This study was registered at UMIN-CTR under registration number UMIN000010672.)

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 79%

Section: Discussioncontrasting

confidence: 79%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity and Safety after Booster Vaccination of Diphtheria, Tetanus, and Acellular Pertussis in Young Adults: an Open Randomized Controlled Trial in Japan

Hara

Okada

Yamaguchi

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

Vaccine chronicle in Japan

Nakayama¹

2013

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

The concept of immunization was started in Japan in 1849 when Jenner’s cowpox vaccine seed was introduced, and the current immunization law was stipulated in 1948. There have been two turning points for amendments to the immunization law: the compensation remedy for vaccine-associated adverse events in 1976, and the concept of private vaccination in 1994. In 1992, the regional Court of Tokyo, not the Supreme Court, decided the governmental responsibility on vaccine-associated adverse events, which caused the stagnation of vaccine development. In 2010, many universal vaccines became available as the recommended vaccines, but several vaccines, including mumps, zoster, hepatitis B, and rota vaccines, are still voluntary vaccines, not universal routine applications. In this report, immunization strategies and vaccine development are reviewed for each vaccine item and future vaccine concerns are discussed.

show abstract

Pertussis Vaccines

Edwards¹,

Decker²

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

Safe and effective booster immunization using DTaP in teenagers

Cited by 22 publications

References 33 publications

Immunogenicity and Safety after Booster Vaccination of Diphtheria, Tetanus, and Acellular Pertussis in Young Adults: an Open Randomized Controlled Trial in Japan

Immunogenicity and Safety after Booster Vaccination of Diphtheria, Tetanus, and Acellular Pertussis in Young Adults: an Open Randomized Controlled Trial in Japan

Vaccine chronicle in Japan

Pertussis Vaccines

Contact Info

Product

Resources

About